Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Chugai and Debiopharm Announce an Exclusive License Agreement for FF284

Published: Tuesday, January 08, 2013
Last Updated: Tuesday, January 08, 2013
Bookmark and Share
Chugai will grant Debiopharm an exclusive license to develop and commercialize FF284 in all countries.

Chugai Pharmaceutical Co., Ltd. and Debiopharm Group™ have announced that on December 17, 2012, they entered into a licensing agreement regarding FF284 (called Debio 1347 by Debiopharm) discovered by Chugai and which is about to start clinical development in oncology.

Under this license agreement, Chugai will grant Debiopharm an exclusive license to develop and commercialize FF284 (Debio 1347) in all countries worldwide including Japan.

Under the same agreement, Chugai will grant a non-exclusive license to develop and commercialize a companion diagnostic for FF284 (Debio 1347).

According to the terms of the license, Debiopharm and Chugai will collaborate to conduct a Phase I dose escalation study. In return for the license, Chugai will receive an upfront fee, milestone and royalty payments from Debiopharm.

“We are delighted that we have concluded a license agreement for the development and marketing of FF284 with Debiopharm” said Tatsuro Kosaka, President and COO of Chugai. “We will continue to cooperate with Debiopharm in order to deliver FF284 to cancer patients as soon as possible.”

“We are happy to combine forces with Chugai for the development of Debio 1347,” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.

Mauvernay continued, “Due to its profile, Debio 1347 is expected to become a tailored treatment with high anti-tumour activity, which is very promising.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Debiopharm Acquires FibroTrap Sample Processing Technology from Spinomix
FibroTrap improves sensitivity and shortens time taken from sample collection to results.
Saturday, June 20, 2015
Debiopharm Announces Phase III Positive Results for Triptorelin 6-month Formulation
Triptorelin 6-month formulation phase III trial demonstrates good efficacy in terms of pituitary and gonadal suppression and in arresting or reversing progression of clinical signs of puberty and slowing down of accelerated bone maturation in children with CPP.
Friday, May 22, 2015
Debiopharm Initiates Clinical Phase II Study to Evaluate Debio 1450
One year after the initiation of Phase I, Debiopharm has announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID.
Friday, May 01, 2015
Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference
Company presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347.
Tuesday, April 21, 2015
Debiopharm Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450
Debio 1450 - A highly potent anti-infective agent selectively active against Staphylococcus species.
Wednesday, October 15, 2014
Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada
Trelstar® one-, three-, and six-month dosing options now available.
Wednesday, October 08, 2014
Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
Both Companies also announces the launch of Pamorelin® LA in Singapore.
Tuesday, May 27, 2014
Debiopharm, Yale University Extend Collaboration
New license and research agreement regarding the discovery of MIF inhibitors.
Wednesday, May 07, 2014
Curis and Debiopharm Report Preclinical Data for Debio 0932
Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC.
Wednesday, April 09, 2014
Debiopharm to Acquire Products or Companies
Company to expand activities at manufacturing facility in Martigny (Valais, Switzerland).
Saturday, March 08, 2014
Immunexpress Closes $6M Financing Round led by Debiopharm
Funding to advance development of the Immunexpress SeptiCyte® technology.
Thursday, March 06, 2014
Debiopharm to Acquire Affinium’s Antibiotic Clinical Assets and Platform
Company acquire clinical and preclinical assets to identify and develop targeted antibiotics.
Wednesday, February 12, 2014
Debiopharm Announces Completion of Recruitment for Phase III Clinical Study in CPP
Completion of recruitment and results are expected in Q4 2014.
Monday, January 20, 2014
Curis and Debiopharm Announce Initiation of Phase I Dose Finding Study of Debio 0932
Designed to target advanced metastatic renal cell carcinoma, the study will determine the maximum tolerated dose of Debio 0932 in combination with everolimus.
Thursday, October 24, 2013
Experimental Therapeutics Centre and Debiopharm Group™ to Collaborate
Collaboration for the development of an epigenetic innovative oncology target.
Tuesday, October 08, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!